Format

Send to

Choose Destination
J Physiol. 2017 Jun 15;595(12):4051-4071. doi: 10.1113/JP273607. Epub 2017 Mar 16.

Proteasome dysfunction in cardiomyopathies.

Author information

1
Department of Neurobiology, Physiology, and Behaviour, University of California, Davis, CA, 95616, USA.
2
Department of Physiology and Membrane Biology, University of California, Davis, CA, 95616, USA.

Abstract

The ubiquitin-proteasome system (UPS) plays a critical role in removing unwanted intracellular proteins and is involved in protein quality control, signalling and cell death. Because the heart is subject to continuous metabolic and mechanical stress, the proteasome plays a particularly important role in the heart, and proteasome dysfunction has been suggested as a causative factor in cardiac dysfunction. Proteasome impairment has been detected in cardiomyopathies, heart failure, myocardial ischaemia, and hypertrophy. Proteasome inhibition is also sufficient to cause cardiac dysfunction in healthy pigs, and patients using a proteasome inhibitor for cancer therapy have a higher incidence of heart failure. In this Topical Review we discuss the experimental data which suggest UPS dysfunction is a common feature of cardiomyopathies, with an emphasis on hypertrophic cardiomyopathy caused by sarcomeric mutations. We also propose potential mechanisms by which cardiomyopathy-causing mutations may lead to proteasome impairment, such as altered calcium handling and increased oxidative stress due to mitochondrial dysfunction.

KEYWORDS:

cardiomyopathies; dilated cardiomyopathy; hypertrophic cardiomyopathy; proteasome; restrictive cardiomyopathy; sarcomere; ubiquitin

PMID:
28181243
PMCID:
PMC5471412
DOI:
10.1113/JP273607
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center